NCT06255223
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
At risk: Primary completion moved 1 year 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 1, 2026 to Dec 1, 2027
- Eligibility criteria expanded, about 31 words
- Study completion pushed from Sep 1, 2026 to Dec 1, 2029
- Secondary endpoints: details revised at 5 of 5 entries
- Notable Eligibility criteria shortened, about 3 wordsv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Disease control rate (DCR)
Timeframe: Up to 1 year
Incidence of adverse events
Timeframe: Up to 1 year
Secondary (5)
Progression-free survival (PFS)
Objective response rate (ORR) (partial response or complete response)
Overall survival (OS)
Abscopal effects
Change of lymphocyte subsets and tumor-associated macrophages (TAMs)
Arms and interventions
Experimental groupExperimental
For eligible subjects, multimodal radiotherapy will be added to the treatment besides original immunotherapy or combinations of immunotherapy and TKIs after adjustment.
Radiation: High-dose Radiotherapy (HDRT), Low-dose Radiotherapy (LDRT)
Drugs: Anti-PD-1 monoclonal antibody
Sites
1 site in 1 country
- Jinling Hospital, Affiliated Hospital of Medical School, Nanjing UniversityNanjing, Jiangsu, China